As shown in Figure 5E, we observed a significant increase in OCN gene expression in both the high-dose LF (100 and 500 μg/mL) and BMP-2-treated groups compared with that of the OM group, whereas 100 and 500 μg/mL LF-treated ADSCs groups showed significantly higher OCN expression than the BMP-2 group. The gene discussed is BGLAP; the disease is ocular melanoma.